Prognostic impact of psoas muscle index in patients with diffuse large B-cell lymphoma might be dependent on the immunochemotherapy type

Leuk Lymphoma. 2021 Oct;62(10):2535-2538. doi: 10.1080/10428194.2021.1919667. Epub 2021 Apr 28.

Authors

Marko Lucijanić^{1

2}, Renata Huzjan Korunić^{2

3}, Martina Sedinić¹, Rajko Kušec^{1

2}, Vlatko Pejša^{1

2}

Affiliations

¹ Hematology Department, University Hospital Dubrava, Zagreb, Croatia.
² University of Zagreb School of Medicine, Zagreb, Croatia.
³ Radiology Department, University Hospital Dubrava, Zagreb, Croatia.

PMID: 33908324
DOI: 10.1080/10428194.2021.1919667

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Humans
Immunotherapy
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Prognosis
Psoas Muscles* / diagnostic imaging
Retrospective Studies
Rituximab / therapeutic use
Vincristine / therapeutic use

Substances

Rituximab
Vincristine
Doxorubicin
Cyclophosphamide